Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Clinical trial data: a culture of transparency
Big Pharma
A new EU policy will require pharmaceutical companies to provide clinical trial data when seeking marketing approval for their drugs. But how will they ensure adequate IP protection while embracing the new culture of transparency? LSIPR reports.   25 November 2014
Patenting Parthenotes
Biotechnology
Earlier this year, the Advocate General of 
the CJEU opined that stem cells from parthenotes are patentable. Franz-Josef Zimmer and Markus Grammel examine the reasoning behind his opinion.   4 November 2014
Pursuing agribusiness infringement actions in Brazil
Americas
Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi.   4 November 2014
Big Pharma
Depositing a microorganism in a country may be crucial for obtaining a method patent in that jurisdiction, but can come with its pitfalls, says Peter ten Haaft.   4 November 2014
Europe
Dennis Waller discusses how differing interpretations of the Bolar exemption may affect clinical trials in the UK.   3 November 2014
Europe
Richard Bassett and Richard Wells look at what EU-based companies must consider in order to comply with the Nagoya Protocol, the regulation aimed at curbing biopiracy.   3 November 2014
Americas
Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications.   3 November 2014
Asia-Pacific
Brand owners may use a multitude of approaches to crack down effectively on fake drugs. Andy Leck and Ren Jun Lim discuss the challenges of anti-counterfeiting efforts in Singapore.   3 November 2014
Americas
AstraZeneca has had a tough few years, with a clutch of patent expiries one of the most serious of its problems. So where does it go from here? To find out, LSIPR spoke to the Anglo-Swedish pharmaceutical company’s vice president of business development about the role IP is playing in its plans for future success.   3 November 2014
Americas
Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry.   3 November 2014